Latigo Biotherapeutics, Inc.
LTGONasdaqCIK 2056611HealthcareFiscal year ends Dec 31
Income statement
| Line item | Unit | period not labelled2025-03-31 | period not labelled2025-06-30 | period not labelled2026-03-31 | Q2 FY20262026-06-30 |
|---|---|---|---|---|---|
| Research and development | $m | not reported | 22.9Research and development, period not labelled, three months to 2025-06-30$22.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported | 21.2Research and development, Q2 FY2026, three months to 2026-06-30$21.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
| Operating income | $m | not reported | (25.7)Operating income, period not labelled, three months to 2025-06-30−$25.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported | (25.8)Operating income, Q2 FY2026, three months to 2026-06-30−$25.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
| Interest expense | $m | not reported | 0.0Interest expense, period not labelled, three months to 2025-06-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported | 0.3Interest expense, Q2 FY2026, three months to 2026-06-30$251.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
| Income tax | $m | not reported | 0.0Income tax, period not labelled, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported | 0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
| Net income | $m | (21.0)Net income, period not labelled, three months to 2025-03-31−$21.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | (25.8)Net income, period not labelled, three months to 2025-06-30−$25.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | (23.0)Net income, period not labelled, three months to 2026-03-31−$23.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | (25.8)Net income, Q2 FY2026, three months to 2026-06-30−$25.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
| Diluted EPS | $ per share | not reported | (36.52)Diluted EPS, period not labelled, three months to 2025-06-30−$36.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported | (27.59)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$27.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
| Basic EPS | $ per share | not reported | (36.52)Basic EPS, period not labelled, three months to 2025-06-30−$36.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported | (27.59)Basic EPS, Q2 FY2026, three months to 2026-06-30−$27.59 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
Balance sheet
| Line item | Unit | period not labelled2024-12-31 | period not labelled2025-03-31 | period not labelled2025-06-30 | period not labelled2025-12-31 | period not labelled2026-03-31 | Q2 FY20262026-06-30 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $m | not reported | not reported | not reported | 69.4Cash and equivalents, period not labelled, at 2025-12-31$69.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported | 55.0Cash and equivalents, Q2 FY2026, at 2026-06-30$55.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
| Current assets | $m | not reported | not reported | not reported | 73.8Current assets, period not labelled, at 2025-12-31$73.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported | 59.2Current assets, Q2 FY2026, at 2026-06-30$59.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
| Total assets | $m | not reported | not reported | not reported | 75.5Total assets, period not labelled, at 2025-12-31$75.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported | 64.8Total assets, Q2 FY2026, at 2026-06-30$64.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
| Current liabilities | $m | not reported | not reported | not reported | 18.4Current liabilities, period not labelled, at 2025-12-31$18.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported | 51.6Current liabilities, Q2 FY2026, at 2026-06-30$51.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
| Total liabilities | $m | not reported | not reported | not reported | 18.6Total liabilities, period not labelled, at 2025-12-31$18.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | not reported | 52.3Total liabilities, Q2 FY2026, at 2026-06-30$52.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
| Shareholders' equity | $m | (130)Shareholders' equity, period not labelled, at 2024-12-31−$129.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | (149)Shareholders' equity, period not labelled, at 2025-03-31−$149.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | (173)Shareholders' equity, period not labelled, at 2025-06-30−$173.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | (232)Shareholders' equity, period not labelled, at 2025-12-31−$231.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | (253)Shareholders' equity, period not labelled, at 2026-03-31−$252.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure | (276)Shareholders' equity, Q2 FY2026, at 2026-06-30−$276.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-03, accession 0001193125-26-381969.Report this figure |
Shares
| Line item | Unit | period not labelled2025-06-30 | Q2 FY20262026-06-30 |
|---|---|---|---|
| Diluted shares (weighted) | k shares | 707 | 935 |
Shares outstanding: 66.30m at Sep 1, 2026, from the cover of the 10-Q filed Sep 3, 2026.
Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.